Hemab Therapeutics shares rose about 13.0% in mid-day trading after the clinical-stage biopharmaceutical company unveiled a multi-part data package and a new pipeline candidate in advance of the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress, which takes place July 11-15 in Paris.
The most prominent clinical detail was first-in-human data for HMB-002 in Von Willebrand disease. According to the company, HMB-002 produced proof of mechanism by raising levels of Von Willebrand Factor and Factor VIII following subcutaneous dosing in Phase 1/2 testing. The company also reported that no thromboembolic events were observed in those studies.
Alongside the HMB-002 readout, Hemab disclosed longer-term extension data for its lead program, sutacimig, in patients with Glanzmann thrombasthenia. Those extension data reportedly showed sustained reductions in annualized treated bleeding rates, a finding the company said supports sutacimig’s clinical profile as it prepares to initiate a Phase 3 trial planned for the second half of 2026.
Hemab further surprised investors by adding a third program to its disclosed pipeline: HMB-003, described as a potent peptide plasmin inhibitor designed to act as a novel antifibrinolytic. The company indicated it intends to begin first-in-human studies for HMB-003 in the second half of 2026.
Sutacimig carries regulatory distinctions intended to reflect the level of unmet need the drug aims to address. The asset has received FDA Breakthrough Therapy designation and also holds Priority Medicines (PRIME) status from the European Medicines Agency.
The breadth of the update - a first-in-human readout, a long-term extension for the lead asset, and the addition of a new candidate - provided the market with a fuller view of Hemab’s development pipeline than had been publicly available, and the company said this package contributed to one of the largest single-session moves in its stock since the firm’s initial public offering earlier this year.
The equity’s jump occurred against a generally positive but modest market backdrop. On the trading day in question, the S&P 500, the Dow Jones Industrial Average and the Nasdaq Composite each rose 0.4%, moves the company noted were too small to explain the magnitude of Hemab’s advance.
Analyst coverage ahead of the announcement had been constructive. Jefferies reiterated a Buy rating with a $39 price target in early June. In late May, Evercore ISI and Wedbush initiated coverage with Outperform ratings.
Investors cited the combined impact of the advancing lead program and the unexpected pipeline expansion as the primary driver of the intraday surge. By delivering clinical confirmation for HMB-002’s mechanism, showing durability for sutacimig in extension data, and revealing HMB-003 as a new antifibrinolytic candidate with first-in-human studies targeted in H2 2026, Hemab expanded the dataset market participants can use to assess the company’s near-term development trajectory.
Context and next milestones
Key upcoming milestones referenced by the company include the Phase 3 start for sutacimig planned in the second half of 2026, and the initiation of first-in-human studies for HMB-003, also targeted for the second half of 2026. The ISTH 2026 Congress will host the nine presentations covering the three programs.